2024-2025 年新冠疫苗在成人中的估计有效性
该研究采用检测阴性病例对照设计,基于 VISION 网络(6 个州、381 个急诊/紧急护理部门和 246 家医院)评估 2024-2025 年新冠疫苗在 ≥18 岁成人中的有效性。接种后 7-299 天内,免疫功能正常成人急诊/紧急护理就诊 VE 为 26%(95%CI 23%-29%),住院 VE 为 35%(95%CI 30%-40%),危重症 VE 为 41%(95%CI 28%-51%)。≥65 岁免疫功能正常成人相应 VE 分别为 26%、35%、41%;免疫功能受损成人住院 VE 为 24%(95%CI 13%-34%)。随接种后时间延长,VE 估计值下降。
要点
- 免疫功能正常成人接种后 7-299 天,急诊/紧急护理就诊 VE 26%(95%CI 23%-29%),住院 VE 35%(95%CI 30%-40%),危重症 VE 41%(95%CI 28%-51%)。
- ≥65 岁免疫功能正常成人急诊/紧急护理就诊 VE 26%(95%CI 22%-30%),住院 VE 35%(95%CI 29%-40%),危重症 VE 41%(95%CI 28%-52%)。
- 免疫功能受损成人住院 VE 24%(95%CI 13%-34%)。
- VE 估计值随接种后时间延长而下降。
- 作者强调成人接种推荐新冠疫苗的重要性。
适用人群与场景
- 美国 ≥18 岁成人,免疫功能正常者纳入急诊/紧急护理就诊和住院分析,免疫功能受损者纳入住院分析。
- 场景为急诊/紧急护理部门和医院,病情阶段为因新冠样疾病就医。
诊断标准与关键阈值
- 病例定义为分子或抗原 SARS-CoV-2 检测阳性且就诊时有新冠样疾病出院诊断码的就诊事件;对照定义为分子 SARS-CoV-2 检测阴性的就诊事件。
- 检测时间窗为就诊日期前 10 天至后 3 天内。
- 疫苗接种暴露定义为就诊前 7-299 天内接种 2024-2025 年新冠疫苗配方。
研究设计与关键结果
- 研究设计为检测阴性病例对照研究,纳入 333 262 次急诊/紧急护理就诊(患者中位年龄 54 岁,女性 60%)和 97 663 次住院(患者中位年龄 72 岁,女性 53%),来自 VISION 网络 6 个州的 381 个急诊/紧急护理部门和 246 家医院。
- 免疫功能正常成人接种后 7-299 天,针对新冠相关急诊/紧急护理就诊的 VE 为 26%(95%CI 23%-29%),针对住院的 VE 为 35%(95%CI 30%-40%),针对危重症的 VE 为 41%(95%CI 28%-51%)。
- ≥65 岁免疫功能正常成人(122 663 次急诊/紧急护理就诊和 63 958 次住院)中,针对急诊/紧急护理就诊的 VE 为 26%(95%CI 22%-30%),针对住院的 VE 为 35%(95%CI 29%-40%),针对危重症的 VE 为 41%(95%CI 28%-52%)。
- 免疫功能受损成人(32 629 次住院)中,针对住院的 VE 为 24%(95%CI 13%-34%)。
- VE 估计值随接种后时间延长而下降。
证据类型、等级与局限
- 证据类型为检测阴性病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 2024-2025 年新冠疫苗接种与免疫功能正常和免疫功能受损成人就医性新冠结局风险降低相关。
- 作者认为,应强调成人接种推荐新冠疫苗的重要性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Vaccine effectiveness (VE) estimates are needed to monitor the effect of updated COVID-19 vaccinations.
OBJECTIVE: To assess the effectiveness of 2024-2025 COVID-19 vaccines against medically attended COVID-19 among adults 18 years and older in the US.
DESIGN, SETTING, AND PARTICIPANTS: This case-control study with a test-negative design included patient encounters with a COVID-19-like illness discharge diagnosis code and a molecular or antigen SARS-CoV-2 test within 10 days before to 3 days after the encounter date, from September 5, 2024, to September 2, 2025. Encounters were captured in VISION (Virtual SARS-CoV-2, Influenza, and Other Respiratory Viruses Network), a multisite, electronic medical record-based network of health care systems, including 381 emergency department/urgent care (ED/UC) departments and 246 hospitals in 6 states.
EXPOSURE: Vaccination with a 2024-2025 COVID-19 vaccine formulation (approved by the US Food and Drug Administration in August 2024) in the previous 7 to 299 days.
MAIN OUTCOMES AND MEASURES: Outcomes were COVID-19-associated ED/UC encounters, COVID-19-associated hospitalization, and COVID-19-associated critical illness (hospitalization with an intensive care unit admission or in-hospital death). Encounters with a positive molecular or antigen SARS-CoV-2 test result were classified as cases, and encounters with a negative molecular SARS-CoV-2 test result were classified as controls. The odds of 2024-2025 COVID-19 vaccination were compared among cases and controls, adjusting for confounders, with estimated VE calculated as (1 - adjusted odds ratio) × 100%.
RESULTS: In 333 262 eligible ED/UC encounters (median [IQR] age of patients, 54 [35-72] years; 60% female) and 97 663 eligible hospitalizations among immunocompetent adults 18 years and older (median [IQR] age of patients, 72 [59-81] years; 53% female), estimated VE was 26% (95% CI, 23%-29%) against COVID-19-associated ED/UC encounters, 35% (95% CI, 30%-40%) against COVID-19-associated hospitalization, and 41% (95% CI, 28%-51%) against COVID-19-associated critical illness 7 to 299 days after vaccination. Among immunocompetent adults 65 years and older (122 663 ED/UC encounters and 63 958 hospitalizations), estimated VE was 26% (95% CI, 22%-30%) against COVID-19-associated ED/UC encounters, 35% (95% CI, 29%-40%) against COVID-19-associated hospitalization, and 41% (95% CI, 28%-52%) against COVID-19-associated critical illness 7 to 299 days after vaccination. Among 32 629 hospitalizations in immunocompromised adults 18 years and older, estimated VE against COVID-19-associated hospitalization was 24% (95% CI, 13%-34%). VE estimates waned with more time since vaccination.
CONCLUSIONS AND RELEVANCE: In this test-negative case-control study, 2024-2025 COVID-19 vaccination was associated with reduced likelihood of medically attended COVID-19-associated outcomes among immunocompetent and immunocompromised adults, highlighting the importance of adults receiving recommended COVID-19 vaccinations.
参考来源
- Wiegand RE, Payne AB, Mak J, et al. Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults. JAMA Intern Med. 2026. PMID: 42295789. doi:10.1001/jamainternmed.2026.1936
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。